Autoantibodies as Biomarkers in Cancer.

Circulating autoantibodies produced by the patient's own immune system after exposure to cancer proteins are emerging as promising biomarkers for the early detection of cancer. An advantage of autoantibodies in cancer detection is their production in large quantities, despite the presence of a relatively small amount of the corresponding antigen. Autoantibodies are also expected to have persistent concentrations and long half-lives due to limited proteolysis and clearance from the circulation. Here, we review current methods for the broad screening of cancer-specific autoantibody targets and the use of such targets to develop clinically relevant assays for the detection of cancer [ABSTRACT FROM AUTHOR]

Copyright of Laboratory Medicine is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)